Multiple mechanisms reduce inflammation, and millions of people around the world are deeply troubled. This chronic disease is expected to usher in a new inhibitor.

Inflammatory bowel disease (IBD) is a chronic disease that affects more than 6.8 million patients worldwide, mainly manifested as Crohn’s disease and ulcerative colitis. Patients suffer from abdominal pain, diarrhea and other symptoms for a long time. Because of its complicated pathogenesis, including heredity, environmental factors, intestinal microbial imbalance and abnormal activation of immune system, there is no radical cure at present, and traditional drug treatment has side effects and some patients have poor response. In a recent study published in Biomedicine & Pharmacotherapy, scientists screened a candidate molecule named KB-0118, which is expected to be used in combination with existing drugs to provide a more efficient and safe treatment scheme. BET family proteins play a key role in gene transcription regulation and have been used in tumor treatment before. However, the application of traditional pan-BET inhibitors is limited because of their high toxicity and short half-life, so the development of new BET inhibitors has become a hot research topic at present. This discovery provides a new hope for the treatment of IBD and other inflammatory diseases.